• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.

作者信息

Konieczny J, Ossowska K, Wolfarth S, Pilc A

机构信息

Department of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 1998 Oct;358(4):500-2. doi: 10.1007/pl00005284.

DOI:10.1007/pl00005284
PMID:9826074
Abstract

The aim of this study was to examine whether (+)-2-aminobicyclo[3.1.0]-hexane-2,6-dicarboxylate monohydrate (LY354740), a selective agonist of group II metabotropic glutamate receptors, possesses antiparkinsonian properties. Parkinsonian-like muscle rigidity was induced by pretreatment with haloperidol (1 mg/kg i.p.). It was measured as increased resistance developed by the rat's hind leg to passive extension and flexion. LY354740 (5 and 10 mg/kg i.p.) dose-dependently diminished the haloperidol-induced muscle rigidity. The present results suggest that LY354740 counteracts the muscle rigidity in an animal model of parkinsonism.

摘要

相似文献

1
LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.
Naunyn Schmiedebergs Arch Pharmacol. 1998 Oct;358(4):500-2. doi: 10.1007/pl00005284.
2
The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity.代谢型谷氨酸受体（mGluR）配体在帕金森病肌肉强直中的作用。
Amino Acids. 2000;19(1):95-101. doi: 10.1007/s007260070038.
3
Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.与（+）-2-氨基双环[3.1.0]己烷-2,6-二羧酸（LY354740）相关的杂双环氨基酸的合成、药理学表征及分子模拟：两种新型强效、选择性且具有全身活性的II型代谢型谷氨酸受体激动剂的鉴定
J Med Chem. 1999 Mar 25;42(6):1027-40. doi: 10.1021/jm980616n.
4
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).一种结构新颖、强效且选择性的代谢型谷氨酸2/3受体激动剂的药理学和药代动力学特性：激动剂(-)-(1R,4S,5S,6S)-4-氨基-2-磺酰基双环[3.1.0]己烷-4,6-二羧酸（LY404039）的体外特性研究
J Pharmacol Exp Ther. 2007 Apr;321(1):308-17. doi: 10.1124/jpet.106.110809. Epub 2007 Jan 4.
5
Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.亲代谢型谷氨酸受体II组激动剂LY354740在精神分裂症阳性症状及认知动物模型中的作用
Behav Pharmacol. 2009 Feb;20(1):56-66. doi: 10.1097/FBP.0b013e3283242f57.
6
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.在健康人类受试者中，通过用II型代谢型谷氨酸受体激动剂LY354740预处理，初步证明N-甲基-D-天冬氨酸（NMDA）谷氨酸受体拮抗剂氯胺酮对工作记忆的破坏作用有所减弱。
Psychopharmacology (Berl). 2005 Apr;179(1):303-9. doi: 10.1007/s00213-004-1982-8. Epub 2004 Aug 10.
7
LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine.LY354740影响惊吓反应，但不影响苯环利定的感觉运动门控或辨别效应。
Eur J Pharmacol. 2000 Jan 28;388(2):R3-4. doi: 10.1016/s0014-2999(99)00844-4.
8
Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.代谢型谷氨酸受体2和3基因敲除小鼠在高架十字迷宫试验中，代谢型谷氨酸受体2/3激动剂LY354740的抗焦虑样活性受到破坏。
Psychopharmacology (Berl). 2005 Apr;179(1):284-91. doi: 10.1007/s00213-004-2098-x. Epub 2004 Dec 24.
9
Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats.代谢型谷氨酸受体5（mGluR5）的阻断在大鼠中产生抗帕金森氏症样效应。
Neuropharmacology. 2001 Sep;41(4):413-20. doi: 10.1016/s0028-3908(01)00083-1.
10
In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).代谢型谷氨酸2/3受体激动剂1S,2S,5R,6S - 2 - 氨基双环[3.1.0]己烷 - 2,6 - 二羧酸单水合物（LY354740）和（ - ） - 2 - 氧杂 - 4 - 氨基双环[3.1.0]己烷 - 4,6 - 二羧酸（LY379268）与多巴胺D2受体缺乏相互作用的体外和体内证据。
J Pharmacol Exp Ther. 2009 Dec;331(3):1126-36. doi: 10.1124/jpet.109.160598. Epub 2009 Sep 15.

引用本文的文献

1
The role of mGluR5 on the therapeutic effects of ketamine in Wistar rats.mGluR5 在氯胺酮治疗 Wistar 大鼠中的作用。
Psychopharmacology (Berl). 2024 Jul;241(7):1399-1415. doi: 10.1007/s00213-024-06571-3. Epub 2024 Mar 9.
2
LY354740 Reduces Extracellular Glutamate Concentration, Inhibits Phosphorylation of Fyn/NMDARs, and Expression of PLK2/pS129 α-Synuclein in Mice Treated With Acute or Sub-Acute MPTP.LY354740可降低急性或亚急性MPTP处理小鼠的细胞外谷氨酸浓度，抑制Fyn/NMDARs的磷酸化以及PLK2/pS129 α-突触核蛋白的表达。
Front Pharmacol. 2020 Feb 28;11:183. doi: 10.3389/fphar.2020.00183. eCollection 2020.
3
In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.
针对帕金森病药物研究的 G 蛋白偶联受体的计算机研究。
Curr Neuropharmacol. 2018;16(6):786-848. doi: 10.2174/1570159X16666180308161642.
4
Enantioselective oxidative gold catalysis enabled by a designed chiral P,N-bidentate ligand.由设计的手性P，N-双齿配体实现的对映选择性氧化金催化。
Angew Chem Int Ed Engl. 2015 Jan 19;54(4):1245-9. doi: 10.1002/anie.201409300. Epub 2014 Nov 27.
5
Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.靶向代谢型谷氨酸受体治疗帕金森病的潜力
Neurodegener Dis Manag. 2012 Apr 1;2(2):221-232. doi: 10.2217/nmt.12.6.
6
Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulata.II 型代谢型谷氨酸受体的激活诱导黑质网状部兴奋性突触传递的长时程抑制。
Neurosci Lett. 2011 Oct 24;504(2):102-106. doi: 10.1016/j.neulet.2011.09.007. Epub 2011 Sep 16.
7
Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease.在帕金森病啮齿动物模型中，选择性激活 mGluR2/3 受体后，与小胶质细胞活化减少相关的神经保护和功能恢复。
Parkinsons Dis. 2010 May 23;2010:190450. doi: 10.4061/2010/190450.
8
Glutamate receptors as therapeutic targets for Parkinson's disease.谷氨酸受体作为帕金森病的治疗靶点。
CNS Neurol Disord Drug Targets. 2009 Dec;8(6):475-91. doi: 10.2174/187152709789824606.
9
Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons.mGlu3 受体的激活可刺激纹状体神经元中 GDNF 的产生。
PLoS One. 2009 Aug 12;4(8):e6591. doi: 10.1371/journal.pone.0006591.
10
Calcium signaling in neurodegeneration.神经退行性疾病中的钙信号转导。
Mol Neurodegener. 2009 May 6;4:20. doi: 10.1186/1750-1326-4-20.